iLABMED, why now and how in the future?

iLABMED Pub Date : 2023-03-28 DOI:10.1002/ila2.5
Hongzhou Lu
{"title":"iLABMED, why now and how in the future?","authors":"Hongzhou Lu","doi":"10.1002/ila2.5","DOIUrl":null,"url":null,"abstract":"<p>Nowadays, public health is facing many challenges, mainly including non-communicable diseases and communicable diseases. Communicable diseases, particularly emerging infectious diseases, have also attracted attention due to their enormous impact on public health and the global economy. The most prominent example is the current global Coronavirus Disease 2019 (COVID-19) pandemic. The unprecedented and ongoing COVID-19 pandemic has highlighted the necessity for readily available, accurate, and rapid laboratory medicine (LM) practices. Nevertheless, current LMs and journals in particular have a window for improvement. First, there are limited numbers of professionals available in this field compared to the other disciplines. The current status quo is that most LM manuscripts must be submitted to comprehensive journals or other journals related to the research disease. Second, most LM journals are run by laboratory personnel who are often more concerned with technical advances than with clinical needs. Lastly, several young LM scientists expressed their desire to have a dedicated platform to discuss, communicate, and publish their works on LM. We were therefore motivated to launch <i>iLABMED</i>, an international public forum dedicated to LMs. The establishment of <i>iLABMED</i> adopts the “four I” strategy, namely “Innovation,” “Intelligence,” “Integration,” and “International.” We are attempting to establish a top-tier journal in the field of LM.</p>","PeriodicalId":100656,"journal":{"name":"iLABMED","volume":"1 1","pages":"1-4"},"PeriodicalIF":0.0000,"publicationDate":"2023-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ila2.5","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"iLABMED","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ila2.5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Nowadays, public health is facing many challenges, mainly including non-communicable diseases and communicable diseases. Communicable diseases, particularly emerging infectious diseases, have also attracted attention due to their enormous impact on public health and the global economy. The most prominent example is the current global Coronavirus Disease 2019 (COVID-19) pandemic. The unprecedented and ongoing COVID-19 pandemic has highlighted the necessity for readily available, accurate, and rapid laboratory medicine (LM) practices. Nevertheless, current LMs and journals in particular have a window for improvement. First, there are limited numbers of professionals available in this field compared to the other disciplines. The current status quo is that most LM manuscripts must be submitted to comprehensive journals or other journals related to the research disease. Second, most LM journals are run by laboratory personnel who are often more concerned with technical advances than with clinical needs. Lastly, several young LM scientists expressed their desire to have a dedicated platform to discuss, communicate, and publish their works on LM. We were therefore motivated to launch iLABMED, an international public forum dedicated to LMs. The establishment of iLABMED adopts the “four I” strategy, namely “Innovation,” “Intelligence,” “Integration,” and “International.” We are attempting to establish a top-tier journal in the field of LM.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
iLABMED,为什么是现在,未来如何?
如今,公共卫生面临许多挑战,主要包括非传染性疾病和传染性疾病。传染病,特别是新出现的传染病,由于对公共卫生和全球经济的巨大影响,也引起了人们的关注。最突出的例子是当前全球2019冠状病毒病(新冠肺炎)大流行。前所未有和持续的新冠肺炎大流行突出了提供现成、准确和快速的实验室医学(LM)实践的必要性。尽管如此,当前的LMs和期刊尤其有改进的窗口。首先,与其他学科相比,该领域的专业人员数量有限。目前的现状是,大多数LM手稿必须提交给综合期刊或其他与研究疾病相关的期刊。其次,大多数LM期刊由实验室人员运营,他们通常更关心技术进步,而不是临床需求。最后,几位年轻的LM科学家表示,他们希望有一个专门的平台来讨论、交流和发表他们在LM上的作品。因此,我们有动力推出iLABMED,这是一个致力于LMs的国际公共论坛。iLABMED的创办采用“四个I”战略,即“创新”、“智能”、“融合”和“国际化”。我们正在努力建立LM领域的顶级期刊。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Issue Information Regulatory factors of ILC2 are therapeutic targets for lung inflammation Etiology, clinical features, and epidemiological analysis of diarrhea patients visiting a gastrointestinal clinic in a comprehensive hospital in Beijing, China, in 2023 A retrospective analysis of the relationship between dermatomyositis-associated interstitial lung disease and disease duration, age, arterial blood gas pH, and serum Cl− levels Ginkgo biloba active compounds can modulate the development of acute mountain sickness and ischemic stroke as discovered by network pharmacology and molecular docking
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1